NEW BRUNSWICK (dpa-AFX) - Janssen-Cilag International NV, a subsidiary of
Johnson & Johnson Co. (JNJ), Friday announced that the European Commission has
approved a Type II variation for Rybrevant in combination with chemotherapy for
the first-line treatment of adult patients with advanced non-small cell lung
cancer with epidermal growth factor receptor exon 20 insertion mutations.

The company said that the approval was based on results from the Phase 3
Papillon study, which demonstrated that Rybrevant plus chemotherapy reduced the
risk of disease progression or death by 60 percent compared to chemotherapy
alone.

Following the approval, the conditional marketing authorisation for Rybrevant
has been changed to a standard marketing authorisation.

Currently, Johnson & Johnson's stock is trading at $146.20, up 0.27 percent on
the New York Stock Exchange.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX